[HTML][HTML] Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia
A Malyukova, M Lahnalampi, T Falqués-Costa… - Genome Biology, 2024 - Springer
Background Targeted therapies exploiting vulnerabilities of cancer cells hold promise for
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia
A Malyukova, M Lahnalampi, T Falqués-Costa… - Genome …, 2024 - researchportal.tuni.fi
Background: Targeted therapies exploiting vulnerabilities of cancer cells hold promise for
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
[PDF][PDF] Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia
A Malyukova, M Lahnalampi, T Falqués, P Pölönen… - researchgate.net
Targeted therapies exploiting vulnerabilities of cancer cells hold promise for improving
patient outcome and reducing side effects of chemotherapy. Yet, mechanistic understanding …
patient outcome and reducing side effects of chemotherapy. Yet, mechanistic understanding …
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia
A Malyukova, M Lahnalampi, T Falqués-Costa… - 2024 - trepo.tuni.fi
Background: Targeted therapies exploiting vulnerabilities of cancer cells hold promise for
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia
A Malyukova, M Lahnalampi… - Genome …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Targeted therapies exploiting vulnerabilities of cancer cells hold promise for
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.
A Malyukova, M Lahnalampi, T Falqués-Costa… - Genome …, 2024 - europepmc.org
Background Targeted therapies exploiting vulnerabilities of cancer cells hold promise for
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
[HTML][HTML] Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia
A Malyukova, M Lahnalampi… - Genome …, 2024 - genomebiology.biomedcentral.com
Targeted therapies exploiting vulnerabilities of cancer cells hold promise for improving
patient outcome and reducing side-effects of chemotherapy. However, efficacy of precision …
patient outcome and reducing side-effects of chemotherapy. However, efficacy of precision …
[HTML][HTML] Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia
A Malyukova, M Lahnalampi, T Falqués-Costa… - Genome …, 2024 - ncbi.nlm.nih.gov
Background Targeted therapies exploiting vulnerabilities of cancer cells hold promise for
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of …
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia
A Malyukova, M Lahnalampi, T Falqués-Costa… - bioRxiv, 2023 - biorxiv.org
Targeted therapies exploiting vulnerabilities of cancer cells hold promise for improving
patient outcome and reducing side-effects of chemotherapy. However, efficacy of precision …
patient outcome and reducing side-effects of chemotherapy. However, efficacy of precision …
[PDF][PDF] Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non‑genetic cancer evolution in acute lymphoblastic leukemia
A Malyukova, M Lahnalampi, T Falqués‑Costa… - 2024 - genomebiology.biomedcentral.com
Background: Targeted therapies exploiting vulnerabilities of cancer cells hold promise for
improving patient outcome and reducing side‑effects of chemotherapy. However, efficacy of …
improving patient outcome and reducing side‑effects of chemotherapy. However, efficacy of …